A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

Exclusion Criteria

• •1. Concomitant diseases that may cause subjects fail to respond to the treatment or confuse the interpretation of the study results;
• •2. Tractional retinal detachment, pre-retinal fibrosis, vitreomacular traction, or epiretinal membrane involving the fovea or disrupting the macular structure in the study eye;
• •3. Active ocular or periocular inflammation/infection in either eye;
• •4. Prior any treatment of following in the study eye:
• •1. Anti-VEGF therapy within 90 days prior to screening;
• •2. Intraocular glucocorticoid injection within 180 days prior to screening;
• •3. Laser photocoagulation or photodynamic therapy within 90 days prior to screening;
• •4. Intraocular surgery within 90 days prior to screening;
• •5. Laser posterior capsulotomy, laser trabeculectomy or laser peripheral iridectomy within 30 days prior to screening;
• •5. Glycated hemoglobin (HbA1c) \> 8% within 28 days prior to screening;
• •6. Uncontrolled hypertension (defined as systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg);
• •7. Systemic administration of steroids within 30 days prior to screening;
• •8. Systemic administration of anti-VEGF drugs within 90 days prior to screening;
• •9. History of severe hypersensitivity/allergic to active ingredients or any excipients of the study drug, or fluorescein and povidone iodine;
• •10. Participated in any clinical study of any other drug within 90 days prior to enrollment, or attempted to participate in other drug trials during the study;
• •11. Other conditions unsuitable for enrollment judged by investigators.